Broken String Biosciences launched BaseMap ABE, a platform for genome-wide off-target characterization supporting adenine base editing therapeutic development. The company says BaseMap ABE produces biologically grounded, genome-wide data directly from relevant cells rather than relying on purely predictive approaches. The launch is framed around the need for standardized characterization as base editing moves from research into therapeutic programs that require reproducible assessment of editor specificity under physiologically relevant conditions. BaseMap ABE is offered through an Early Access Program intended to support guide optimization, editor selection, and preclinical decision-making. For base editing developers, the product targets a recurring translational bottleneck: how to compare programs on off-target risk with consistent, data-rich methods that regulators and partners can evaluate.